Should I buy or sell Hoth Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOTH shares. View HOTH analyst ratings or view top-rated stocks .

What is Hoth Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price. View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts .

How have HOTH shares performed in 2024?

Hoth Therapeutics' stock was trading at $1.44 at the beginning of 2024. Since then, HOTH stock has decreased by 18.8% and is now trading at $1.17. View the best growth stocks for 2024 here .

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 218,100 shares, an increase of 698.9% from the March 15th total of 27,300 shares. Based on an average daily trading volume, of 473,500 shares, the short-interest ratio is currently 0.5 days. Currently, 5.0% of the company's stock are short sold. View Hoth Therapeutics' Short Interest .

When is Hoth Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our HOTH earnings forecast .

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($3.50) earnings per share for the quarter, missing the consensus estimate of ($3.38) by $0.13.

When did Hoth Therapeutics' stock split?

Hoth Therapeutics shares reverse split on the morning of Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR) , Ocugen (OCGN) , Fulcrum Therapeutics (FULC) , Heat Biologics (HTBX) , Tonix Pharmaceuticals (TNXP) , AIM ImmunoTech (AIM) , Aytu BioPharma (AYTU) , Gilead Sciences (GILD) , iBio (IBIO) and Nabriva Therapeutics (NBRV) .

When did Hoth Therapeutics IPO?

Hoth Therapeutics (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HOTH

Hoth Therapeutics (HOTH) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free HOTH Stock Alerts

$1.16

-0.02 (-1.69%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.16
▼
$1.23
50-Day Range: $1.15
▼
$1.65
52-Week Range: $0.99
▼
$4.30

Volume: 22,183 shs
Average Volume: 412,098 shs
Market Capitalization: $5.67 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Hoth Therapeutics alerts:

Hoth Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 241.9% Upside
$4.00 Price Target
Short Interest: Bearish
5.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.33 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Hoth Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.00% of the float of Hoth Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Hoth Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Hoth Therapeutics has recently increased by 698.90%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Hoth Therapeutics does not currently pay a dividend.
Dividend Growth
Hoth Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HOTH.

2.4

News and Social Media Coverage

News Sentiment
Hoth Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
4 people have searched for HOTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
3 people have added Hoth Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.29% of the stock of Hoth Therapeutics is held by insiders.
Percentage Held by Institutions
Only 7.08% of the stock of Hoth Therapeutics is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Hoth Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Hoth Therapeutics is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Hoth Therapeutics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Banyan Hill Publishing

Is AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)

Rare Chance to Be an Early Investor in AI Energy Breakthrough Technology expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors.

Just go here for full details.

About Hoth Therapeutics Stock (NASDAQ:HOTH)

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

HOTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HOTH Stock News Headlines

April 12, 2024 | msn.com

Hoth Therapeutics files to sell 5.03M shares of common stock for holders

April 2, 2024 | msn.com

The Brickyard, Carlisle to welcome popular rock band Elias T Hoth

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 27, 2024 | prnewswire.com

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

March 27, 2024 | prnewswire.com

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

March 19, 2024 | marketwatch.com

Hoth Therapeutics Shares Soar on Positive Data from Alzheimer's Study

March 19, 2024 | msn.com

Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?

March 19, 2024 | finanznachrichten.de

Hoth Therapeutics, Inc.: Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 19, 2024 | msn.com

Graphite Bio, SCWorx, Acurx Pharmaceuticals among healthcare movers

March 19, 2024 | markets.businessinsider.com

Hoth Therapeutics: Pre-clinical Research Shows HT-ALZ's Profound Impact On Alzheimer's Pathology

March 19, 2024 | msn.com

Hoth stock rallies 24% on preclinical Alzheimer's data

March 19, 2024 | prnewswire.com

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

February 29, 2024 | finance.yahoo.com

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

February 26, 2024 | finanznachrichten.de

Hoth Therapeutics, Inc.: Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

February 26, 2024 | markets.businessinsider.com

Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment

February 26, 2024 | prnewswire.com

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

February 13, 2024 | finance.yahoo.com

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

February 6, 2024 | markets.businessinsider.com

Buy Rating for Hoth Therapeutics: Promising HT-001 Prospects and Diverse Clinical Pipeline

January 18, 2024 | finanznachrichten.de

Hoth Therapeutics, Inc.: Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

January 18, 2024 | markets.businessinsider.com

Hoth Therapeutics Received FDA Clearance To Broaden HT-001 Clinical Trial

January 18, 2024 | marketwatch.com

Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments

January 18, 2024 | msn.com

Hoth stock jumps on FDA approval of study expansion for HT-001

January 18, 2024 | finance.yahoo.com

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

December 27, 2023 | msn.com

Hoth Therapeutics, SCWorx among healthcare movers

December 27, 2023 | msn.com

Why Hoth Therapeutics Shares Are Rising Today

December 27, 2023 | finance.yahoo.com

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami

See More Headlines

Receive HOTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hoth Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:HOTH
CUSIP: N/A
CIK: 1711786
Web: www.hoththerapeutics.com
Phone: (646) 756-2997
Fax: N/A
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +227.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,840,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -76.28%
Return on Assets: -66.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.89
Quick Ratio: 13.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.03 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 4,890,000
Free Float: 4,728,000
Market Cap: $5.97 million
Optionable: Not Optionable
Beta: 0.63

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Robb Knie (Age 55)
President, CEO & Chairman
Comp: $844.01k
Mr. David S. Briones (Age 48)
Chief Financial Officer
Ms. Hayley Springer
Executive Vice President of Operations

Key Competitors

View All Competitors

HOTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Hoth Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HOTH shares.
View HOTH analyst ratings or view top-rated stocks.
What is Hoth Therapeutics' stock price target for 2024?: 1 Wall Street analysts have issued 12-month price targets for Hoth Therapeutics' shares. Their HOTH share price targets range from $4.00 to $4.00. On average, they anticipate the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 241.9% from the stock's current price.
View analysts price targets for HOTH or view top-rated stocks among Wall Street analysts.
How have HOTH shares performed in 2024?: Hoth Therapeutics' stock was trading at $1.44 at the beginning of 2024. Since then, HOTH stock has decreased by 18.8% and is now trading at $1.17.
View the best growth stocks for 2024 here.
Are investors shorting Hoth Therapeutics?: Hoth Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 218,100 shares, an increase of 698.9% from the March 15th total of 27,300 shares. Based on an average daily trading volume, of 473,500 shares, the short-interest ratio is currently 0.5 days. Currently, 5.0% of the company's stock are short sold.
View Hoth Therapeutics' Short Interest.
When is Hoth Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our HOTH earnings forecast.
How were Hoth Therapeutics' earnings last quarter?: Hoth Therapeutics, Inc. (NASDAQ:HOTH) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($3.50) earnings per share for the quarter, missing the consensus estimate of ($3.38) by $0.13.

When did Hoth Therapeutics' stock split?: Hoth Therapeutics shares reverse split on the morning of Wednesday, October 26th 2022. The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Hoth Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu BioPharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).
When did Hoth Therapeutics IPO?: Hoth Therapeutics (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.
How do I buy shares of Hoth Therapeutics?: Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HOTH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Hoth Therapeutics (HOTH) Stock Price, News & Analysis

Hoth Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Hoth Therapeutics Stock (NASDAQ:HOTH)

HOTH Stock Price History

HOTH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

HOTH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™